Publications by authors named "Markus Harder"

Claim this Profile
D
Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
Markus J Harder, Britta Höchsmann, Arthur Dopler, Markus Anliker, Christof Weinstock

Front Immunol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Comment on "Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1".
Arthur Dopler, Leonie Guntau, Markus J Harder, Annette Palmer, Britta Höchsmann

J Immunol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy.
Nadine Beha, Markus Harder, Sarah Ring, Roland E Kontermann, Dafne Müller

Mol Cancer Ther· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1.
Arthur Dopler, Leonie Guntau, Markus J Harder, Annette Palmer, Britta Höchsmann

J Immunol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay.
Markus Anliker, Christoph Q Schmidt, Markus J Harder, Georgi Ganchev, Inge von Zabern

Transfusion· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biophysical analysis of sialic acid recognition by the complement regulator Factor H.
Christoph Q Schmidt, Agnes L Hipgrave Ederveen, Markus J Harder, Manfred Wuhrer, Thilo Stehle

Glycobiology· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.
Markus J Harder, Nadine Kuhn, Hubert Schrezenmeier, Britta Höchsmann, Inge von Zabern

Blood· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
Christoph Q Schmidt, Markus J Harder, Eva-Maria Nichols, Mario Hebecker, Markus Anliker

Immunobiology· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation.
Markus J Harder, Markus Anliker, Britta Höchsmann, Thomas Simmet, Markus Huber-Lang

J Immunol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Inhibitors and Monoclonal Antibodies That Modulate the Interaction between Plasmodium falciparum Adhesin PfRh4 with Its Erythrocyte Receptor Complement Receptor 1.
Nicholas T Y Lim, Markus J Harder, Alexander T Kennedy, Clara S Lin, Christopher Weir

J Biol Chem· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.
Vanessa Kermer, Nora Hornig, Markus Harder, Anastasiia Bondarieva, Roland E Kontermann

Mol Cancer Ther· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis